$284.49
+1.03
(+0.36%)▲
2.76%
Downside
Day's Volatility :4.58%
Upside
1.87%
57.9%
Downside
52 Weeks Volatility :60.08%
Upside
5.16%
Period | Madrigal Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 46.62% | 6.5% | 0.0% |
6 Months | 25.44% | 7.1% | 0.0% |
1 Year | 40.79% | 9.8% | 0.0% |
3 Years | 231.84% | 14.2% | -20.2% |
Market Capitalization | 6.1B |
Book Value | $41.13 |
Earnings Per Share (EPS) | -23.14 |
PEG Ratio | 0.0 |
Wall Street Target Price | 365.33 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -40.13% |
Return On Equity TTM | -88.78% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -453.6M |
Diluted Eps TTM | -23.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -27.94 |
EPS Estimate Next Year | -17.78 |
EPS Estimate Current Quarter | -6.28 |
EPS Estimate Next Quarter | -6.61 |
What analysts predicted
Upside of 28.42%
Sell
Neutral
Buy
Madrigal Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Madrigal Pharmaceuticals, Inc. | 2.94% | 25.44% | 40.79% | 231.84% | 235.85% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Madrigal Pharmaceuticals, Inc. | NA | NA | 0.0 | -27.94 | -0.89 | -0.4 | NA | 41.13 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Madrigal Pharmaceuticals, Inc. | Buy | $6.1B | 235.85% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Madrigal Pharmaceuticals, Inc.
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 20.8%
HHG PLC
Baker Bros Advisors LP
venBio Select Advisor LLC
Paulson & Company Inc
Vanguard Group Inc
BlackRock Inc
Madrigal Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read Moremadrigal pharmaceuticals inc. is a biotechnology company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.
Organization | Madrigal Pharmaceuticals, Inc. |
Employees | 376 |
CEO | Dr. Rebecca A. Taub M.D. |
Industry | Health Technology |
Outfront Media Inc.
$284.49
+0.36%
Blackrock Short Duration Bond Etf
$284.49
+0.36%
Helmerich & Payne, Inc.
$284.49
+0.36%
Crane Nxt Co
$284.49
+0.36%
Liberty Global Plc - Class C Shares
$284.49
+0.36%
Waystar Holding Corp.
$284.49
+0.36%
Apogee Therapeutics
$284.49
+0.36%
Wd-40 Co
$284.49
+0.36%
Nnn Reit Inc.
$284.49
+0.36%